Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cartesian Therapeutics (RNAC) EBITDA Margin (2016 - 2026)

Cartesian Therapeutics (RNAC) has disclosed EBITDA Margin for 12 consecutive years, with 50242.31% as the latest value for Q1 2026.

  • For Q1 2026, EBITDA Margin fell 4863522.0% year-over-year to 50242.31%; the TTM value through Mar 2026 reached 16496.52%, up 1661131.0%, while the annual FY2025 figure was 32564.25%, 3236191.0% down from the prior year.
  • EBITDA Margin hit 50242.31% in Q1 2026 for Cartesian Therapeutics, down from 6383.79% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 6383.79% in Q4 2025 and bottomed at 50242.31% in Q1 2026.
  • Average EBITDA Margin over 5 years is 3914.12%, with a median of 177.59% recorded in 2023.
  • Year-over-year, EBITDA Margin skyrocketed 564879bps in 2025 and then plummeted -4863522bps in 2026.
  • Cartesian Therapeutics' EBITDA Margin stood at 34.92% in 2022, then crashed by -6254bps to 2149.07% in 2023, then skyrocketed by 134bps to 735.0% in 2024, then soared by 769bps to 6383.79% in 2025, then plummeted by -887bps to 50242.31% in 2026.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 50242.31%, 6383.79%, and 7945.13% for Q1 2026, Q4 2025, and Q3 2025 respectively.